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Abstract
The EGFR (epidermal growth factor receptor) is involved in the oncogenesis of many tumors. In addition to the full-length
EGFR (isoform a), normal and tumor cells produce soluble EGFR isoforms (sEGFR) that lack the intracellular domain. sEGFR
isoforms b, c and d are encoded by EGFR variants 2 (v2), 3 (v3) and 4 (v4) mRNA resulting from gene alternative splicing.
Accordingly, the results of EGFR protein expression analysis depend on the domain targeted by the antibodies. In
meningiomas, EGFR expression investigations mainly focused on EGFR isoform a. sEGFR and EGFRvIII mutant, that encodes
a constitutively active truncated receptor, have not been studied. In a 69 meningiomas series, protein expression was
analyzed by immunohistochemistry using extracellular domain targeted antibody (ECD-Ab) and intracellular domain
targeted antibody (ICD-Ab). EGFRv1 to v4 and EGFRvIII mRNAs were quantified by RT-PCR and EGFR amplification revealed
by MLPA. Results were analyzed with respect to clinical data, tumor resection (Simpson grade), histological type, tumor
grade, and patient outcome.Immunochemical staining was stronger with ECD-Ab than with ICD-Ab. Meningiomas
expressed EGFRv1 to -v4 mRNAs but not EGFRvIII mutant. Intermediate or high ECD-Ab staining and high EGFRv1 to v4
mRNA levels were associated to a better progression free survival (PFS). PFS was also improved in women, when tumor
resection was evaluated as Simpson 1 or 2, in grade I vs. grade II and III meningiomas and when Ki67 labeling index was
lower than 10%.Our results suggest that, EGFR protein isoforms without ICD and their corresponding mRNA variants are
expressed in meningiomas in addition to the whole isoform a. EGFRvIII was not expressed. High expression levels seem to
be related to a better prognosis. These results indicate that the oncogenetic mechanisms involving the EGFR pathway in
meningiomas could be different from other tumor types.
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Introduction
Meningiomas are the second most common primary intracra-
nial tumor [1]. According to the World Health Organization
(WHO) classification, they consist of grade I (meningothelial,
psammomatous, fibroblastic, angiomatous and transitional); grade
II (atypical, chordoid and clear cells), which have a high rate of
recurrence; and grade III tumors (anaplastic, papillary, rhabdoid),
which are highly malignant. Meningiomas infiltrating adjacent
brain tissue are considered to be grade II [2].
Epidermal growth factor receptor gene (EGFR/ErbB1) is a
member of the ErbB receptor tyrosine kinase family. EGFR
overexpression has been reported in a majority of human tumors
[3,4,5,6]. Recent therapeutic agents that target EGFR such as
monoclonal antibodies and small-molecule tyrosine kinase inhib-
itors constitute an important progress in various cancer treatments
[7,8,9,10].
EGFR is composed of three main domains: an extracellular
domain (ECD), a transmembrane domain (TMD), and an
intracellular domain (ICD). In addition to the full-lenght
transmembrane forms, soluble EGFR (sEGFR) isoforms, that
comprised solely the ECD portions of the receptor, have been
detected in normal and malignant cells, in tissues, and in biological
fluids [11,12]. These sEGFR proteins can be either generated by
alternative mRNA splicing events or via proteolytic cleavage of the
receptor [13,14]. EGFR gene alternative splicing leads to four
transcripts: EGFR variants 1, 2, 3 and 4 (v1, v2, v3 and v4,
respectively) mRNA that encode 170-kDa whole receptor and 60-
kDa [15], 80-kDa [16,17] and 110-kDa [18] sEGFR isoforms,
respectively. Another 110-kDa soluble EGFR isoforms known as
PI-sEGFR are produced by proteolytic cleavage triggered in part
by metalloproteases [11,12,19,20]. In addition, an aberrant
translocation event was found in A431 vulvar carcinoma cell line
resulting in the expression of a 115-kDa sEGFR [21]. Circulating
sEGFR level have been used as prognosis and theragnosis
predictive markers in the serum of patients with cervical [22],
colorectal [23], ovarian and breast [24,25,26,27]. The predictive
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cervical or lung cancer [28,29].
Since alternative splicing can produce different isoforms, it is
critical to know which epitope recognize the antibodies when
studying EGFR protein expression. Indeed, others and we
reported strong difference in immunohistochemical labeling
according to the EGFR domain, ECD or ICD, targeted by
primary antibodies [5,28,30].
In meningiomas, the role of EGFR signaling pathway in tumor
genesis and the usefulness of EGFR investigation in regard to
prognosis and/or theragnosis assessment remain unclear and
discrepancies exist. Some studies reported higher EGFR protein
levels in grade I and grade II meningiomas compared to grade III
meningiomas [31,32]. Smith et al. reported shorter survival times
for patients having atypical meningiomas with low EGFR protein
levels [33]. Depending on studies, the percentage of meningiomas
that overexpress EGFR varied from 40 to 100%,
[31,34,35,36,37,38,39]. In addition, the nature of the cells
(endothelial or tumor cells), expressing EGFR protein has also
been discussed [34,38,40,41]. The lack of consensus in meningi-
omas regarding EGFR can be attributed to primary antibodies
used in immunohistochemistry (IHC) [30,42] or to primer
locations when RT-PCR approaches were used. sEGFR have a
potential role in activating or inhibiting the EGFR pathway and
their expression pattern can be of major interest for potential
therapeutic applications in meningioma [43,44].
In addition to EGFR overexpression, EGFR gene amplification
is another common genetic alteration found in glioma, non small
cells lung cancers or colorectal tumors. However, in meningiomas
no such alteration was described [40]. EGFR amplification is often
associated with the expression of a constitutively active EGFRvIII
mutant, in which a portion of ECD is missing. EGFRvIII has been
detected in glioblastomas [45], breast, ovarian, prostate or lung
cancers [46,47] but never studied in meningiomas.
In the present study, we investigated the EGFR expression
pattern of meningiomas. EGFR isoforms were assessed on IHC
with EGFR ECD-Antibody (ECD Ab) that recognized all isoforms
and with ICD-Antibody (ICD-Ab) that recognized only isoform a
(EGFR full length receptor) and EGFRvIII. We then investigated
their corresponding mRNA levels by Quantitative RT-PCR
(EGFR v1, v2, v3, v4 and vIII mutant mRNAs). Finally, EGFR
gene amplification was assessed by Multiplex Ligation-dependant
Probe Amplification (MLPA). These data were analyzed with
respect to tumor grade and to patient outcome. To our knowledge,
it is the first report on meningiomas that compared the difference
in IHC staining between ECD and ICD EGFR antibodies and
that studied the expression level of mutant EGFRvIII and sEGFR-
encoding transcripts.
Material and Methods
Patients and Tissue Samples
We studied 69 meningiomas obtained from adult patients
undergoing surgery at Limoges Dupuytren University Hospital
between 1995 and 2009. All samples were used in accordance with
French bioethics laws regarding patient information and consent.
Ethics approval was obtained from the ‘‘comite ´m e ´dico-scientifi-
que de la tumorothe `que de l’Ho ˆpital Dupuytren’’, the bioethics
committee of our hospital. Before storage in the tumor bank,
samples are anonymized when received in the Pathology
Department and only the number of anonymity, age and sex are
provided to users. Out of 69 patients, 38 underwent surgery for
intracranial meningiomas from 1996 to 2004. In agreement with
our bioethics committee’s procedure, no information was given to
and no written or verbal consent was obtained from these patients
because samples were already collected and referred to research
prior the French bioethical law (2004). From 2005, the new
French law on Bioethics applies. The law states that patients 1)
must be informed of the possible use of their samples for research
purposes 2) should not have expressed their refusal to the use of
their samples for research purposes. However, the law does not
specify whether the information or the refusal must be collected
verbally or in a written form. Thus in our Institution, patients who
underwent surgery are verbally informed and only in cases of
refusal their written opposition is recorded. In that case, samples
are no longer eligible for research purposes. This procedure has
been validated and implemented by the bioethics committee of our
Institution.
Clinical, radiological, therapeutic and survival data were
obtained by a retrospective query. In 67 cases, surgical resection
could be evaluated according to the Simpson grade which was
determined from the surgical records [48]. No patients had
received EGFR-targeted chemotherapy. At the time of resection,
tumor samples were fixed in 4% formalin, embedded in paraffin
and sections were stained with hemalum phloxin saffron. A part of
the surgical specimen was snap frozen and stored at 280uC. The
histological tumor types and grade of meningiomas were
determined according to the WHO classification. Histologically
benign meningiomas but presenting a brain invasion were
classified as grade II [2]. In cases where a preoperative
embolization was performed (height tumors), we interpreted the
presence of necrosis as secondary to embolization and not as true
tumor necrosis.
Quantitative RT-PCR
Total RNA extraction. Before RNA extraction, hemalum
phloxin-stained sections of the frozen tissue were prepared and
examined to ensure that the tissue samples were located in
representative areas of the tumors. Tumor tissue (5 to 30 mg) was
incubated with 1 mL QiazolH solution (Qiagen, Courtaboeuf,
France) and CK14 ceramic beads (Ozyme) and pulverized two
times for 40 sec each at 6,500 rpm in Precellys 24 homogenizer
(Ozyme). Homogenized tissues were lysed and RNA purification
was performed according to the manufacturer’s protocol (‘‘RNeasy
lipid tissue kit’’, Qiagen). A DNase I digestion step was included
for each extraction to prevent contamination of the RNA by
genomic DNA. RNA concentration and purity was estimated by
spectrophotometry (NanoDrop ND1000, Labtech France). RNA
quality was assessed by capillary electrophoresis (Bioanalyzer
2100, Agilent Technologies) and only RNAs with an integrity
number .6 were used for analysis. Eight patients were excluded
from analysis due to the absence of tumor tissue or to RNA
degradation after extraction.
Quantitative and Qualitative RT-PCR
Complementary DNA (cDNA) was synthesized from 2 mgo f
total RNA using the Transcriptor First Strand cDNA SynthesisH
kit (Roche) and hexamer primers according to manufacturer’s
protocol. Primers sequence and locations were carefully selected to
amplify EGFRv1-vIII, EGFRv2, EGFRv3, EGFRv4, EGFRvIII
and hypoxanthine phosphoribosyl transferase (HPRT) as previ-
ously described [5]. For quantitative PCR of v1, v2, v3, v4
transcripts, HPRT was used to normalize results, based on
previous comparative experiments. Specific amplification of
EGFRvIII mRNA was considered as qualitative for the following
reason: the 59 forward primer was designed to overlap exon1-
exon8 boundary for specificity purpose but PCR generated primer
dimers that did not allow accurate quantification. However, on the
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37204Figure 1. ECD-Ab and ICD-Ab targeting. EGRF gene contains 30 exons and generates 5 different mRNAs. Variant 1 mRNA encodes the whole
EGFR isoform a. Alternative splicing generates variant mRNAs 2, 3, and 4 that encode sEGFR isoforms b, c and d respectively. EGFRvIII mutant mRNA
with a 801 bp (exons 2–7) deletion produces EGFR vIII that lack amino acids 2 to 273. ECD-Ab targets EGFR extracellular domain and recognizes
sEGFR and vIII mutant, whereas ICD-Ab targets EGFR intracellular domain and recognizes EGFR isorform a and vIII mutant.
doi:10.1371/journal.pone.0037204.g001
Table 1. Distribution according to histopathological type and grade.
All Grade I
a Grade II
a Grade III
a
w. brain inv. w/o. brain inv. w. brain inv. w/o. brain inv. w. brain inv. w/o. brain inv.
n 6 9 02 91 4 1 952
Tumor histology
Microcystic 1 – 1 – – – –
Fibrous 9 – 9 – – – –
Transitional 18 – 13 5 – – –
Meningothelial 14 – 6 8 – – –
Clear cells 1 – – – 1 – –
Atypical 12 – – 1 11 – –
Chordoid 7 – – – 7 – –
Malignant 7 – – – – 5 2
aTumors with or without brain invasion (w. brain inv. and w/o. brain inv.) were distinguished.
doi:10.1371/journal.pone.0037204.t001
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down to 10 copies. PCR were performed on a Rotor Gene
thermocycler (Corbett Research) using the ‘‘Light Cycler Fast
Start DNA Master SYBR Green I’’ kit (Roche). All targets were
amplified in the presence of 3 mM MgCl2 and 0.5 mM primers.
The mRNA levels were quantified using the DDCt method
((Ctsample2Ctcalibrator)interest gene2(Ctsample2Ctcalibrator)reference gene),
modified according to Pfaffl [49], with efficiency correction by the
Rotor Gene Software, and were expressed in relative arbitrary
units (R.A.U.). For each interest gene, values were normalized as
follows: Samplex mRNA rate = Raw Samplex mRNA rate/
mean1Rn raw mRNA rate.
Multiplex Ligation-Dependent Probe Amplification
(MLPA) Procedure and Data Processing
EGFR gene amplification was studied using the MLPA
technique with the SALSA P105 (MRCHolland, http://www.
eurogentest.org/uploads/1247475007479/MLPA_validation re-
port_TJ_version1_2009 0710.pdf). MLPA was performed on
35/69 patients randomly selected in grade I (14/29) and grade
II (14/33) tumors, and in all grade III meningiomas (7/7). Four
normal control DNA samples, isolated from blood of healthy
volunteers, were included in MLPA experiment and for data
processing. Probes contained in MLPA SALSA P105 hybridized
11 of the 30 exons of EGFR gene, and also contained 8 control
probes located on chromosome without known abnormalities in
meningiomas. Probe sequences and location are available on the
manufacturer site.
MLPA was performed as described by the manufacturer with
minor modifications. Briefly, DNA (30 ng) was dissolved in 5 mlo f
TE-buffer (10 mmol/L Tris, pH 8.2, 1 mmol/L ethylenediamine-
tetraacetic acid, pH 8.0), denatured, and subsequently cooled to
25uC. After adding the probe mix, the sample was denatured, and
the probes were allowed to hybridize (16 hours at 60uC). After
ligation of both probe pairs and inactivation of ligase, PCR was
performed in a volume of 50 ml containing 10 ml of the ligation
reaction mixture using the PTC 200 thermal cycler (MJ Research
Inc., Waltham, MA) (35 cycles of denaturation at 95uC for 30
seconds, annealing at 60uC for 30 seconds, and extension at 72uC
for 1 minute with a final extension of 20 minutes at 72uC).
Fragments were separated and quantified by electrophoresis on an
ABI 3130 XL capillary sequencer (Applied Biosystems, Foster
City, CA) and Genemapper analysis (Applied Biosystems).
Data analysis was performed in Excel using a ‘‘in house’’
method modified from Jeuken et al., 2006 [50] : first, the fraction
of each peak was calculated by dividing the peak area value of
each probe amplification product by the combined value of the
control probes within the sample, to compensate for PCR
efficiency of the individual samples. Subsequently this relative
peak value or so-called probe fraction is divided by the mean
probe fraction of this fragment within the included reference
DNAs, generating the normalized peak value or the so-called
probe ratio.
Values obtained for six negative samples (blood samples Nu1–3
and glioma samples Nu4–6 with unamplified EGFR) were used as
reference to set theoretical threshold [51] at 0.5 to identify DNA
losses and at 2 for DNA gains. Based on values obtained for a
glioma sample with an amplified EGFR (sample Nu8), polysomy or
amplification was concluded when values above 2 was reached for
all EGFR exons.
Immunohistochemistry
After representative areas of tumor tissue were selected using
hemalum phloxin saffron-stained sections, five mm-thick sections
were cut from paraffin-embedded blocks. Sections were incubated
with Ki67 antibody (clone MiB-1, DakoCytomation, Glostrup,
Denmark; 1/200
e), EGFR ECD-Ab (clone 3C6, Ventana Medical
System, France; pure) and EGFR ICD-Ab (clone EGFR.25,
Novocastra Laboratories, United Kingdom; 1/500
e), (Figure 1).
Sample slides were processed automatically (BenchMark XT ICH/
ISH, Ventana Medical Systems, USA) according to protocols
supplied by the antibody manufacturers. For each section, we
recordedthetypeofcellexpressingEGFRprotein,thepercentageof
labeled cells, the labeling intensity and the resulting Hirsch score as
previously described [52,53,54,55,56,57]. For Ki67 labeling index,
10% of labeled cells was taken as a cut-off value for analyses.
Statistical Analyses
Statistical analyses were performed with StatViewH 5.0 (SAS
Institute, Inc., Cary, NC, U.S.A.) and PAST 2.08 b (http://folk.
uio.no/ohammer/past, [58]) software. A correlation between
quantitative variable was assessed with Pearson r test. Fisher’s
exact test was used to assess differences between nominal variables.
Means variations according to variables were compared with the
Student-t test. Progression free survival (PFS) and overall survival
(OS) were analyzed by Kaplan-Meier and median PFS or OS
medians were compared with the non-parametric logrank. Results
for which p,0.05 were considered to be statistically significant.
Results
Tumor Characteristics
Histopathological features of the 69 meningiomas are given in
Table 1. Tumors locations were cerebral convexity (n=39), falx
(n=5), parasagittal (n=5), paratentorial (n=1) regions and skull
Table 2. Relationship between tumor grade, demographic
data, Simpson grade, absence or presence of tumor necrosis
and Ki67 labeling index.
All Grade I Grade II Grade III p
N 69 29 33 7
Age (median) 56.8 57 58.2 48.2 ,0.05
Sex
Men 26 7 13 6 0.01
Women 43 22 1 1
Simpson Grade
12 2 8 1 3 1 0.1
2 3 6 1 91 43
3 4 130
4 5 122
n.a. 2 - 1 1
Tumor Necrosis
Y e s 1 8 3960.0008
No 43 22 20 1
Preoperative
embolization
8 44-
Ki67 Labeling
Index
,10% 55 29 25 1 ,0.0001
$10% 14 0 8 6
doi:10.1371/journal.pone.0037204.t002
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shown). Relationship between demographical data, histological
grade, Simpson grade, presence or absence of tumor necrosis and
Ki67 labeling index is indicated in Table 2.
Immunohistochemical Detection of EGFR Proteins
ECD-Ab and ICD-Ab targeted extracellular and intracellular
EGFR domain respectively (Figure 1). Labeling localizations were
slightly different according to manufacturer indications (Figure 1).
ECD-Ab stained membrane and cytoplasm of tumor cells (Figure 2
A and C) while staining with ICD-Ab was almost always restricted
to the cytoplasm (Figure 2 B and D). In three cases, a staining was
observed in both endothelial and tumor cells with the ECD-Ab.
Asshownonimmunohistochemicalsections(Figure2A,B,C,D),
staining intensity, percentage of stained cells and resulting Hirsch
Scores were significantly higher for ECD-Ab than those obtained
withICD-Ab(p,0.0001,Figure2E).Allmeningiomaswerelabeled
with ECD-Ab, 78% (54/69 cases) of them having a strong labeling
(Table3).Incontrast,only45%ofthetumorswerelabeledwithICD-
Abandallofthempresentedonlyloworintermediatelabeling.Allbut
Figure 2. EGFR immunohistochemistry. (A and B) Grade I transitional meningioma and (C and D) grade II chordoid meningioma: tumor cells
showed a very strong labeling, membranous and cytoplasmic, with ECD-Ab (A and C) while rare cells were labeled, mainly within the cytoplasm, with
the ICD-Ab (B and D); (E) Labeling parameters are presented for ECD-Ab and ICD-Ab.
doi:10.1371/journal.pone.0037204.g002
Table 3. Comparison for ECD-Ab and ICD-Ab score labeling.
ECD-Aba
+++ ++ + No
ICD-Aba +++ –– – –
++ 3– – –
+ 24 3 1 –
No 27 8 3 –
aECD-Ab and ICD-Ab labeling was expressed as Hirsch score: strong (+++, score
301–400), intermediate (++, score 201–300), low (+, score 1–200), no expression
(No, score 0).
doi:10.1371/journal.pone.0037204.t003
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Ab staining, whereas tumors with low or intermediate ECD-Ab
labeling were not orverylightly stained withICD-Ab.
ECD-Ab and ICD-Ab labeling score was not associated with
patient age, sex, absence or presence of tumor necrosis, brain
invasion and tumor grade (Table 4). We observed that ICD-Ab
Table 4. Relationship between immunohistochemical EGFR detection and clinicopathological parameters.
n ECD-Ab Hirsch Score ICD-Ab Hirsch Score
Mean ± SD p Mean ± SD p
All 69 367.7673.4 23.5658.8
Sex
Male 26 366.5679.6 .0.99 28670.7 0.4
Female 43 366.7669.9 16643.8
Age (years)
#56.8 34 360.9673.6 0.5 18.5650.6 0.8
.56.8 35 372.6673.3 22.6660.4
Simpson Grade
12 2 3 5 4 . 1 685.3 0.3 (1 vs.3 or 4) 17.5646.2 0.06 (1 vs. 4)
23 6 3 7 3 . 1 666.8 0.4 (2 vs. 1 or 3) 11.7639 0.01 (2 vs. 4)
3 4 400606 0 6120 0.08 (2 vs. 3)
4 5 356698.4 746102.9
Brain Invasion
Yes 19 371.6671.3 0.7 1.864.5 0.08
No 50 364.8674.4 27.6663.6
Tumor Necrosis
Yes 43 356.7690.3 0.6 31669.2 0.4
No 18 369.3670.3 18.4653.5
Histological Grade
I2 9 3 8 2 . 8 638.4 0.1 (I vs. II) 23.2652.9 0.3 (I vs. III)
II 33 355.2691.1 0.2 (I vs. III) 22.4662.9 0.4 (II vs. III)
III 7 354.3685.4 0.661
Ki67 Labeling Index
,10% 55 377.8656.2 0.01 17.3646.9 0.3
$10% 14 322.96110.6 33.3681.5
doi:10.1371/journal.pone.0037204.t004
Figure 3. Expression of EGFR variant mRNA. EGFR v1, v2, v3 and v4 mRNA levels were expressed in R.A.U.
doi:10.1371/journal.pone.0037204.g003
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Ab labeling was inversely related to Ki67 labeling index (p=0.01)
(Table 4).
EGFRv1, v2, v3, v4 and EGFRvIII Mutant mRNA Levels and
their Association with other Tumor Variables
All meningiomas expressed EGFR v1, v3 and v4 mRNA
whereas only 50% of the tumors expressed EGFRv2 mRNA.
Table 5. MLPA results for EGFR gene amplification.
N6 Type Ex 1 Ex 2 Ex 3 Ex 4 Ex 5 Ex 6 Ex 7 Ex 8 Ex 13 Ex 16 Ex 22
1 Negative control 1.13 0.90 0.91 1.36 1.03 0.51 0.82 0.84 1.01 1.40 1.37
2 Negative control 1.55 0.83 1.00 1.31 1.13 0.50 0.91 0.98 0.94 1.79 1.34
3 Negative control 1.46 1.08 0.98 1.66 1.03 0.38 0.94 1.01 0.88 1.59 1.41
4 Negative control 1.62 1.92 1.54 1.88 1.39 0.60 1.48 1.34 1.70 1.75 2.19
5 Negative control 1.21 0.67 0.74 1.32 1.04 0.84 0.82 1.23 1.00 1.28 1.05
6 Negative control 1.27 2.34 1.57 1.89 1.24 0.66 1.63 1.74 1.78 1.65 1.74
7 Positive control 32.47 30.97 32.07 33.89 28.50 26.44 26.05 35.51 28.88 31.53 30.17
8 Grade I 1.83 1.33 1.24 1.41 1.28 0.61 1.07 1.23 1.22 1.87 1.50
9 Grade I 1.47 0.55 0.80 1.21 0.92 0.50 0.93 1.07 0.95 1.17 0.89
10 Grade I 1.59 0.56 0.75 1.11 1.10 0.77 1.04 1.24 1.27 1.30 0.74
11 Grade I 1.35 0.67 0.74 1.09 1.00 0.57 0.83 1.04 1.00 1.20 0.90
12 Grade I 1.34 0.75 0.70 1.09 1.10 0.64 0.90 0.99 0.95 0.99 0.87
13 Grade I 1.42 0.60 0.75 1.07 1.17 0.92 0.98 0.92 0.99 1.24 1.06
14 Grade I 1.49 0.62 0.61 0.89 0.88 0.48 0.73 0.71 0.83 1.00 1.15
15 Grade I 0.75 0.35 0.61 0.57 0.73 0.40 0.48 0.64 0.58 0.63 0.58
16 Grade I 1.75 0.65 0.91 1.22 1.28 0.72 0.98 1.04 0.93 1.31 1.36
17* Grade I 1.08 0.61 0.87 1.31 1.02 0.64 0.93 1.00 0.89 1.39 0.84
18* Grade I 1.26 0.62 0.68 0.96 0.84 0.54 0.78 0.91 0.93 0.65 0.75
19 Grade I 1.53 0.79 1.10 1.62 1.24 0.75 1.05 1.31 1.19 1.31 1.31
20 Grade I 1.12 1.07 0.84 1.24 1.05 0.60 0.79 0.98 0.83 1.42 1.33
21 Grade II 1.36 0.61 0.72 1.21 1.00 0.71 0.96 0.89 0.99 1.15 0.96
22 Grade II 1.58 0.48 0.67 0.83 1.11 0.89 0.95 1.13 1.20 1.01 0.97
23 Grade II 1.56 0.61 0.86 1.31 1.29 0.81 1.23 1.23 1.30 1.34 1.13
24 Grade II 2.45 1.22 1.27 1.89 1.79 1.29 1.62 1.69 1.89 1.46 1.83
25 Grade II 1.35 0.52 0.83 1.19 1.35 0.85 1.04 1.24 1.37 0.93 1.21
26 Grade II 1.40 0.46 0.63 0.84 0.89 0.50 0.81 0.79 1.04 0.92 0.92
27 Grade II 1.04 0.32 0.45 0.72 0.70 0.39 0.63 0.74 0.60 0.67 0.59
28 Grade II 1.46 0.67 0.86 1.30 0.93 0.57 0.93 1.07 0.97 1.15 1.10
29 Grade II 1.67 0.63 1.01 1.25 0.89 0.79 1.04 1.20 0.88 1.33 0.94
30 Grade II 1.25 0.52 0.75 1.07 0.83 0.88 1.00 1.17 1.19 0.93 0.85
31 Grade II 1.47 0.90 0.99 1.35 1.05 0.84 1.06 1.25 1.27 1.43 1.05
32 Grade II 1.52 0.64 1.17 1.35 1.10 0.92 1.15 1.47 1.11 1.17 1.09
33 Grade II 1.27 0.80 1.07 1.29 1.00 0.77 0.89 1.31 1.17 1.22 1.09
34 Grade II 1.37 0.55 0.87 0.99 1.05 1.11 1.17 1.50 1.27 0.93 0.86
35 Grade II 2.23 0.77 0.93 1.24 1.43 1.86 2.18 2.75 2.22 1.57 1.12
36 Grade III 0.76 0.37 0.34 0.73 0.64 0.48 0.63 0.56 0.61 0.67 0.44
37 Grade III 1.02 0.34 0.52 0.81 1.12 0.83 1.03 0.90 1.16 0.93 0.92
38 Grade III 0.76 0.30 0.62 0.88 1.33 1.24 1.14 1.02 0.86 0.96 0.99
39 Grade III 1.35 0.74 0.74 1.34 0.95 0.67 1.09 1.27 1.05 0.85 0.95
40 Grade III 2.18 1.12 1.09 1.94 1.47 1.00 1.58 2.01 1.64 1.87 1.33
41 Grade III 2.47 1.12 1.36 1.77 1.90 1.39 1.95 2.48 1.71 1.51 1.61
42 Grade III 1.10 0.77 0.97 1.20 0.86 0.64 0.88 1.43 0.85 0.75 0.80
Negative controls were healthy volunteers blood (Nu1–3) or glioma with no EGFR amplification as validated by a standard FISH technic (Nu4–6). Positive control was
glioblastoma harboring EGFR amplification as validated by a standard FISH technic (Nu7). *Cases Nu17 and 18 were chosen to illustrate MLPA results on figure 4. Lack of
amplification was concluded for 2.Ratio,0.5, and amplification for ratio .3 (bold values). 2,Ratio.0.5 were considered as not interpretable (underlined values).
doi:10.1371/journal.pone.0037204.t005
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EGFR v3. EGFRv1. EGFR v2 (Figure 3). Moreover, except for
EGFRv2 mRNA, each EGFR variant mRNA levels were
straightly correlated with each other (p,0.0001, data not shown).
The EGFRvIII mutant mRNA was never detected.
There was no significant association between any variant
mRNA levels with demographic variable, Simpson grade, brain
invasion, tumor type and grade or Ki67 labeling index (results not
shown).
MLPA Results for EGFR Amplification
MLPA results are given in the Table 5. Examples of the MLPA
profiles are presented in Figure 4. Values ,0.5 or .2 did not
reflect a loss or a gain when found only on certain exon and were
considered as not interpretable, probably due to variability in
DNA quality. Compared to a glioma sample with an amplified
EGFR, none of the analyzed meningiomas showed EGFR gene
amplification.
Relationship with Tumor Progression Free Survival and
Overall Survival
At the time of our analysis, the tumors of nine patients had
recurred (out of 69) and were all grade III meningiomas. PFS was
significantly better for women and for patients having Simpson
grade 1 and 2 tumors, grade I vs. grade II vs. grade III tumors and
for meningiomas with a KI67 labeling index less than 10%
(Table 6; Figure 5A, B, C). Taken individually, the expression of
each mRNAs variant was not significantly link to PFS (Table 6).
However, when mRNAs variant expression was analyzed as a
whole, high levels were correlated with a better PFS (Figure 5D;
Table 6). A better PFS were also found with patients whose tumors
were strongly labeled with ECD-Ab. No such link could be drawn
with ICD-Ab (Figures 5E and 5F respectively). Regarding OS,
Simpson grade 1 and 2, absence of brain invasion, grade I and II,
and Ki67 labeling index less than 10% were related with a better
prognosis (Table 6).
Discussion
Epidermal Growth Factor Receptor is involved in many tumors,
with alterations ranging from protein overexpression, gene
amplification, and gene mutation. EGFR is also alternatively
spliced giving rise to four different isoforms, three of which lacking
tyrosine kinase domain. In meningiomas, the second most
common intracranial tumor, EGFR expression analysis gave
conflicting results particularly on IHC, depending on the antibody
used. Hence, the usefulness of EGFR as a potential prognosis or
theragnosis marker is questionable.
In this study we described the EGFR-based profiling of
meningiomas. EGFR was analyzed at protein, genetic, and
transcriptomic levels. Results were confronted to histological and
clinical data.
Figure 4. EGFR gene amplification. Genomic DNAs from glioma with and without EGFR amplification were used as positive and negative controls
respectively. Two examples of results obtained for meningioma are presented.
doi:10.1371/journal.pone.0037204.g004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37204In a 69 meningiomas series, we showed that IHC analysis
revealed an ECD-Ab staining significantly stronger than that with
the ICD-Ab. Whereas ICD-antibodies only target whole EGFR
and the EGFRvIII mutant, the ECD-antibodies also detect
sEGFR like isoforms b, c and d as shown by Halle and coworkers
in cervical cancers [28]. Our IHC results suggest that meningi-
omas express other EGFR isoforms than the whole receptor, but
do not indicate which ones. However, transcriptional analysis of
EGFR variants indicated that all isoforms were present in our
series (see below).
Our findings clearly show that IHC data should be interpreted
according to the antibody used to investigate EGFR expression.
Antibodies directed against the EGFR ECD do not recognize the
same isoforms as antibodies directed against the ICD and this
might explain the discrepancies found in the literature concerning
EGFR expression. EGFR has been reported to be expressed in
meningiomas at frequencies greater than 60%
[31,34,35,36,37,38,39] and even as high as 100% [59], which is
similar to our results with ECD-Ab but not with ICD-Ab. These
findings are not only reported in meningiomas but have also been
described in other tumor types and with other EGFR antibodies
[5,28,30,60,61,62].
In addition to whole EGFR, tumor cells express sEGFR
proteins that can be generated by alternative mRNA splicing
events [13,14,15,16,18], via proteolytic cleavage of the receptor
[11,12,13,20] or by aberrant translocation events [21]. In our
series, we found that meningiomas expressed the alternatively
spliced mRNA transcripts v2, v3 and v4. That suggests that the
EGFR b, c and d isoforms are likely to be produced by
meningiomas and supports our immunohistochemical results.
These results suggest that the EGFR signaling pathway, including
EGFR mRNA variant expression, could be involved in meningi-
omas oncogenesis. However, we did not find any specific mRNA
expression pattern that correlated with the histological tumor type
and grade.
EGFR gene amplification, associated or not to EGFRvIII
mutant expression, is frequently observed in other tumors like
gliomas [5,52,63,64,65,66], lung cancers [67,68], breast [69], and
prostate adenocarcinomas [70]. EGFR gene amplification and
EGFRvIII transcripts were not detected in our series, indicating
that they are not involved in meningiomas oncogenesis.
Regarding the roles of the EGFR pathway in oncogenesis, the
expression pattern of this receptor in meningiomas seems
somewhat paradoxical. The EGFR pathway is known to play
important roles in cell proliferation, resistance to apoptosis,
adhesion, motility, invasion and angiogenesis, all of which are
characteristic features of tumor progression. Consequently, EGFR
overexpression in many tumors, such as head and neck
carcinomas, is associated with malignancy and more aggressive
phenotypes [71]. These characteristics represent the basis of anti-
EGFR targeted therapies used in clinical oncology. Conversely, in
our series of meningiomas, high levels of EGFR expression were
associated with a better clinical outcome, as previously reported
[31,32]. Physiopathological mechanisms of EGFR expression
remain poorly understood and different hypotheses have been
proposed. It has been suggested that the EGFR pathway in
meningiomas is stimulated by an autocrine/paracrine mechanism
that occurs in association with other control systems [31,72]. The
ultimate result is that EGFR pathway activity is either positively or
negatively regulated. Thus, activation of the EGFR pathway could
represent a first step in meningiomas oncogenesis, whereas
transformation in more aggressive tumors and/or the development
of primary grade III meningiomas could result from additional
oncogenic mechanisms.
The roles of the different EGFR isoforms are largely unknown
in tumor pathology. Albitar et al. reported isoform expression in
cell cultures of endometrial adenocarcinoma [73]. Some studies
indicate that soluble isoforms could regulate EGFR signaling in
normal [17] and in tumor tissues [74]. Truncated EGFR isoforms
have been shown to decrease cellular proliferation in vitro [16,75].
The mechanisms responsible for growth inhibition could be
competitive binding of EGFR ligands by the soluble isoforms
[76,77] and formation of inactive heterodimers between different
isoforms, which competitively prevent the formation of functional
holoreceptors and reduce intracellular kinase activity [74]. In our
series, the presence of EGFR mRNAs suggests that a particular
regulatory mechanism of EGFR signaling could exist in menin-
giomas. Patients whose tumors produced high levels of v1–v4
mRNAs presented a better PFS. Moreover, improved PFS was
associated with a strong or intermediate ECD-Ab staining but not
with ICD-Ab labeling. That might indicate that truncated isoforms
could act as negative regulators.
Prognosis and theragnosis predictive values have been shown
for sEGFR levels in blood and in tumor tissues of certain cancers
[22,23,24,25,26,27,28,29]. These isoforms may compete with
active, membrane-bound receptors for the binding of therapeutic
Table 6. OS and PFS according to clinical, pathological and
molecular parameters.
PFS
a OS
b
Median
(months)
p Median
(months)
p
Age
#56.8/.56.8 nr/nr 0.82 nr/nr 0.3
Gender
Male/Female 45.8/nr 0.002 nr/nr 0.4
Simpson Grade
1/2/3/4 nr/nr/3.6/15.2 ,0.0001nr/nr/nr/19.2 0.03
Brain Invasion
No/yes nr/nr 0.67 nr/nr 0.003
Histological Grade
I vs. II vs. III nr/nr/37 n.a. nr/nr/19.2 0.01
Ki67 Labeling Index
,10% vs. $10% nr 15.54 ,0.0001nr nr 0.03
ECD-Ab (Hirsch Score)
Low vs. Interm vs. High 15.9/nr/nr 0.04 19.2/nr/nr n.a.
ICD-Ab (Hirsch Score)
No vs. Low vs. Interm nr/nr/nr 0.2 nr/nr/nr n.a.
EGFR variant mRNA Levels
c
EGFRv1 Weak vs. Strong nr/nr 0.5 nr/nr 0.4
EGFRv2 Weak vs. Strong nr/nr 0.9 nr/nr 0.5
EGFRv3 Weak vs. Strong nr/nr 0.1 nr/nr 0.5
EGFRv4 Weak vs. Strong nr/nr 0.4 nr/nr 0.1
SEGFRv1v2v3v4 Weak vs.
Strong
51.3/nr 0.04 nr/nr 0.5
aProgression free survival (PFS).
bOverall survival (OS).
cMedian values were used as cut-off to determinate weak and strong levels for
each variant or sum (S) of all variants.
doi:10.1371/journal.pone.0037204.t006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37204Figure 5. Patient PFS according to clinical and biological parameters. Probability of progression free durvival (PFS) was expressed in months,
according to Simpson grade (A), histological tumor grade (B), Ki67 labeling index (C), EGFRv1v2v3v4 mRNA levels (D), ECD-Ab labeling (E), and ICD-Ab
labeling (F).
doi:10.1371/journal.pone.0037204.g005
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37204antibodies, which could thus explain why some EGFR-targeted
therapies failed [61,78,79]. In meningiomas, intracellular EGFR
inhibitors, like Gefitinib or Erlotinib have been shown to be
inefficient [43]. Regarding our results, this could be due to an
overexpression of sEGFR rather than entire EGFR isoforms, since
these inhibitors are ineffective on EGFR isoforms that lack the
ICD.
Finally, several studies have shown that treatment outcomes,
with regards to EGFR, are also dependent on serum ligand levels.
Several reports showed relation between circulating EGF and
patient treatment outcomes in different types of cancers. However,
we think that quantifying serum ligand levels goes beyond the
scope of our study. First, our study was retrospective and patient
serums were not available. We focused our work on the analysis of
EGFR isoform expression. Second, the purpose of the present
article was to show that like a number of other tumors (lung,
ovarian, breast, gliomas), meningiomas expressed EGFR isoforms
other than the whole one (isoform a), and this may have important
implications in the assessment of EGFR expression, particularly by
immunohistochemistry, or for the development of new therapies.
In conclusion, we observed that, in addition to the entire EGFR
isoform a (HER1), meningiomas expressed EGFR receptors
lacking the ICD that was sustained by the strong expression of
the EGFR transcripts encoding sEGFR isoforms. No EGFR gene
amplification was detected and we did not found any mutant vIII
expression. Furthermore, a better prognosis was associated to a
strong staining with an antibody targeted against the ECD and
high EGFR transcript levels. This suggests that the oncogenetic
mechanisms involving the EGFR gene pathway in meningiomas
could be different from other tumor types.
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